Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Immunotherapy with anti-PD1 antibodies provides encouraging results on a subset of patients.
Capmatinib, a MET inhibitor, has shown an imunomodulatory effect and a synergy with
spartalizumab a PD-1 inhibitor. The purpose of this phase II trial is to evaluate the
efficacy and safety of the combination of capmatinib + spartalizumab in adult patients with
advanced oesogastric adenocarcinoma.